latest news releases from the newsroom
Dow Jones Indexes
Dow Jones Indexes and Citigroup to Launch First Islamic Bond Index
NEW YORK, March 6, 2006 (PRIMEZONE) -- Dow Jones Indexes and Citigroup Corporate and Investment Banking, both leading global index providers, today announced that they intend to launch the Dow Jones Citigroup Sukuk Index, the first index that seeks to measure the performance of global bonds complying with Islamic investment guidelines.
SeaDrill Limited -- Mandatory Offer to Purchase Shares in Smedvig ASA
HAMILTON, Norway, March 6, 2006 (PRIMEZONE) -- We refer to the press release dated 20 February 2006 where SeaDrill Limited ("SeaDrill") stated its intention to make a mandatory offer for all of the outstanding Class A and Class B shares in Smedvig ASA ("Smedvig") pursuant to the rules of the Norwegian Securities Trading Act (the "Mandatory Offer").
Stolt-Nielsen S.A. and Nutreco N.V. Reach Agreement to Sell Entire Shareholding in Marine Harvest to Geveran Trading Co. Ltd.
LONDON, March 6, 2006 (PRIMEZONE) -- Stolt-Nielsen S.A. (Nasdaq:SNSA)(Oslo:SNI) and Nutreco Holding N.V. announced today an agreement to sell their entire shareholding in the aquaculture company Marine Harvest N.V. to the investment fund Geveran Trading Co. Ltd. for total cash proceeds of approximately EUR 1.175 billion, plus the assumption of all of Marine Harvest's debt of approximately EUR 150 million. SNSA currently owns 25% of Marine Harvest and Nutreco owns 75%. SNSA expects to realize cash proceeds of approximately $350 million from the sale of its share of Marine Harvest and a gain of approximately $80 million.
Jerini AG Presents Clinical Development Update for Icatibant in the Treatment of Hereditary Angioedema
BERLIN, March 6, 2006 (PRIMEZONE) -- Jerini AG (FSE:J14) announced today that clinical trial progress from its ongoing Phase III clinical trial for hereditary angioedema (HAE) was presented by Dr. Alvin Davis, Harvard Medical School, at the American Academy of Allergy Asthma and Immunology Conference (AAAAI) on March 4, 2006 in Miami, Florida. Dr. Davis reported that 153 subcutaneous open-label treatments with Icatibant have been administered for abdominal, cutaneous, and laryngeal HAE attacks, with 91 percent of patients being treated with only a single injection within 24 hours. Eight percent of patients received a second injection and one percent received three injections within 24 hours. In the ongoing Phase III trials, patients completing the randomised study phase are eligible to receive Icatibant in the open-label study phase (for ethical reasons, laryngeal attacks, which are potentially life-threatening are only treated in the open-label phase). In addition, 48 percent of participating Phase III patients have been treated with Icatibant in multiple HAE attacks, with one patient receiving more than 30 treatments.
ATA Airlines, Inc.
ATA Reports February Scheduled Service Traffic
INDIANAPOLIS, March 5, 2006 (PRIMEZONE) -- ATA Airlines, Inc., today reported that February scheduled service traffic decreased 49.4 percent from 2005 to 266.0 million RPMs (revenue passenger miles). Capacity decreased 58.3 percent compared to 2005 to 375.2 million ASMs (available seat miles). ATA's February scheduled service passenger load factor increased 12.5 points to 70.9 percent. There were 182,642 passengers enplaned in February, a decrease of 57.6 percent.
Murray, Frank & Sailer LLP
Investor Notice: A Shareholder Class Action Has Been Filed Against Take-Two Interactive Software, Inc. -- TTWO
NEW YORK, March 3, 2006 (PRIMEZONE) -- Murray, Frank & Sailer LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, on behalf of shareholders who purchased or otherwise acquired the securities of Take-Two Interactive Software, Inc. ("Take-Two" or the "Company") (Nasdaq:TTWO) between October 25, 2004 and January 27, 2006, inclusive (the "Class Period"). Murray, Frank & Sailer LLP is seeking to pursue remedies under the Securities Exchange Act of 1934 against defendants Take-Two, Paul Eibeler, Karl H. Winters, and Gary Lewis (the "defendants").